Abstract
Rosiglitazone often results in weight gain. We hypothesized that rosiglitazone may modulate circulating levels of ghrelin and peptide YY3–36 and this modulation may be related to weight-gaining effect of this agent. This study was designed as an open-label, randomized, controlled trial of 3-month duration. Women with newly diagnosed type 2 diabetes were studied. Twenty-eight of the 55 eligible participants were randomly assigned to receive rosiglitazone (4 mg/d). Twenty-seven patients with diabetes matched for age and body mass index served as controls on diet alone. We evaluated the effects of 3 months of rosiglitazone treatment on fasting peptide YY3–36 and ghrelin levels, and anthropometric measurements. The 3-month administration of rosiglitazone reduced fasting plasma peptide YY3–36 levels by 25%, the between-group difference was statistically significant. No effect of this thiazolidinedione compound on fasting ghrelin concentrations was observed at the end of study. The ghrelin/body mass index ratio also did not change significantly after treatment. Seventy-five percent of the women with diabetes complained of increased hunger at the end of study. Nevertheless, all subjects exhibited a decrease in fasting PYY levels after 3 months of rosiglitazone therapy, irrespective of the levels of hunger. There was no significant correlation between changes in peptide YY3–36 and those in anthropometric parameters and insulin sensitivity at the end of the study. Rosiglitazone-induced decrease in fasting peptide YY3–36 levels may in part contribute to orexigenic and weight-gaining effect of this thiazolidinedione derivative.
Similar content being viewed by others
References
Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117(1):13–23. doi:10.1172/JCI30227
Wynne K, Bloom SR (2006) The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2(11):612–620. doi:10.1038/ncpendmet0318
Baynes KC, Dhillo WS, Bloom SR (2006) Regulation of food intake by gastrointestinal hormones. Curr Opin Gastroenterol 22(6):626–631. doi:10.1097/01.mog.0000245537.43142.63
Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, Fujimiya M (2004) Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 18(3):439–456. doi:10.1096/fj.03-0641rev
Kojima M, Hosoda H, Date Y, Nakazato M, Kanagawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–660. doi:10.1038/45230
Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, Hale JE (2008) Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 105(17):6320–6325. doi:10.1073/pnas.0800708105
Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132(3):387–396. doi:10.1016/j.cell.2008.01.017
Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, Schürmann A, Joost HG, Jandacek RJ, Hale JE, Heiman ML, Tschöp MH (2009) GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15(7):741–745. doi:10.1038/nm.1997
Kamegai J, Tamura H, Shimizu T, Ishii S, Suighara H, Wakabayashi I (2000) Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141(12):4797–4800. doi:10.1210/en.141.12.4797
Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50(2):227–232. doi:10.2337/diabetes.50.2.227
Zhang W, Zhao L, Lin TR, Chai B, Fan Y, Gantz I, Mulholland MW (2004) Inhibition of adipogenesis by ghrelin. Mol Biol Cell 15(5):2484–2491. doi:10.1091/mbc.E03-09-0657
Batterham RL, Bell JD, Chandarana K, Chivers JE, Heffron H, Herzog H, Kapoor S, Le Roux CW, Thomas EL, Withers DJ (2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4(3):223–233. doi:10.1016/j.cmet.2006.08.001
Chelikani PK, Haver AC, Reidelberger RD (2004) Comparison of the inhibitory effects of PYY(3–36) and PYY(1–36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 287(5):R1064–R1070. doi:10.1152/ajpregu.00376.2004
Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR Jr (2000) Primary structures of PYY, [Pro(34)]PYY, and PYY-(3–36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 279(1):G126–G131
Popovic V, Duntas LH (2005) Brain somatic cross-talk: Ghrelin, leptin and ultimate challengers of obesity. Nutr Neurosci 8(1):1–5. doi:10.1080/10284150400027107
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349(10):941–948
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953–12956. doi:10.1074/jbc.270.22.12953
Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4(4):611–617. doi:10.1016/S1097-2765(00)80211-7
Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14(11):1293–1307. doi:10.1101/gad.14.11.1293
Fidan E, Onder Ersoz H, Yilmaz M, Yilmaz H, Kocak M, Karahan C, Erem C (2011) The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 23 Mar. [Epub ahead of print] PubMed PMID: 21424914. doi:10.1007/s00592-011-0276-y
Wang AP, Li X, Zheng Y, Liu BL, Huang G, Yan X, Liu Z, Zhou Z (2010) Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms. Acta Diabetol 10 Dec. [Epub ahead of print] PubMed PMID: 21153483. doi:10.1007/s00592-010-0239-8
Scheen AJ (2002) Glitazones and weight gain. Ann Endocrinol (Paris) 63:IS412–IS414
Hermansen K, Mortensen LS (2007) Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 30(12):1127–1142
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46(2):145–154. doi:10.1007/s00592-008-0090-3
Lebovitz HE (2002) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18(Suppl 2):S23–S29. doi:10.1002/dmrr.252
Barnett AH (2002) Insulin-sensitizing agents-thiazolidinediones (glitazones). Curr Med Res Opin 18(Suppl 1):S31–S39
De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98(4):1004–1009. doi:10.1172/JCI118860
Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG (1996) Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271(16):9455–9459. doi:10.1074/jbc.271.16.9455
Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, Williams G (1997) Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 122(7):1405–1410. doi:10.1038/sj.bjp.0701535
Larsen PJ, Jensen PB, Sørensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K (2003) Differential influences of peroxisome proliferator-activated receptors γ and -α on food intake and energy homeostasis. Diabetes 52(9):2249–2259. doi:10.2337/diabetes.52.9.2249
Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M (1998) Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21(9):1470–1474. doi:10.2337/diacare.21.9.1470
American Diabetes Association (2001) Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 24(Suppl 1):S44–S47
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β–cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. doi:10.1007/BF00280883
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141(11):4325–4328. doi:10.1210/en.141.11.4325
Le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147(1):3–8. doi:10.1210/en.2005-0972
Korner J, Inabnet W, Conwell I-M, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M (2006) Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14(9):1553–1561. doi:10.1038/oby.2006.179
Guo Y, Ma L, Enriori PJ, Koska J, Franks PW, Brookshire T, Cowley MA, Salbe AD, Delparigi A, Tataranni PA (2006) Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 14(9):1562–1570. doi:10.1038/oby.2006.180
Nakahara R, Kojima S, Tanaka M, Yasuhara D, Harada T, Sagiyama K, Muranaga T, Nagai N, Nakazato M, Nozoe S, Naruo T, Inui A (2007) Incomplete restoration of the secretion of ghrelin and PYY compared to insulin after food ingestion following weight gain in anorexia nervosa. J Psychiatr Res 41(10):814–820. doi:10.1016/j.jpsychires.2006.07.021
Pfluger PT, Kampe J, Castaneda T, Vahl T, D’Alessio DA, Kruthaupt T, Benoit SC, Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AFH, Koebnick C, Weickert MO, Otto B, Spranger J, Tschop MH (2007) Effect of human body weight changes on circulating levels of peptide YY and peptide YY3–36. J Clin Endocrinol Metab 92(2):583–588. doi:10.1210/jc.2006-1425
Yildirim S, Bolkent S, Sundler F (2008) The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study. J Mol Histol 39(6):635–642. doi:10.1007/s10735-008-9204-z
Ali-Rachedi A, Varndell IM, Adrian TE, Gapp DA, Noorden SV, Bloom SR, Polak JM (1984) Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochem Cell Biol 80(5):487–491. doi:10.1007/BF00495439
Böttcher G, Sjöberg J, Ekman R, Hakanson R, Sundler F (1993) Peptide YY in the mammalian pancreas: immunocytochemical localization and immunochemical characterization. Regul Pept 43(3):115–130. doi:10.1016/0167-0115(93)90146-Y
Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M (2005) PYY3–36 as an anti-obesity drug target. Obes Rev 6(4):307–322. doi:10.1111/j.1467-789X.2005.00218.x
Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML, Withcomb DC (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430(6996):1. doi:10.1038/nature02665
Menghini R, Marchetti V, Cardellini M, Hribal ML, Mauriello A, Lauro D, Sbraccia P, Lauro R, Federici M (2005) Phosphorylation of GATA2 by Akt increases adipose tissue differentiation and reduces adipose tissue-related inflammation: a novel pathway linking obesity to atherosclerosis. Circulation 111(15):1946–1953. doi:10.1161/01.CIR.0000161814.02942.B2
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesäniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L (2007) Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 156(2):263–269. doi:10.1530/eje.1.0233138
Kusaka I, Nagasaka S, Horie H, Ishibashi S (2008) Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 10(11):1039–1046. doi:10.1111/j.1463-1326.2008.00857.x
Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 59(3):373–379. doi: 10.1016/j.metabol.2009.08.005
Hutchinson DS, Summers RJ, Bengtsson T (2008) Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther 119(3):291–310. doi:10.1016/j.pharmthera.2008.05.008
Schimmack G, Defronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8(6):591–602. doi:10.1111/j.1463-1326.2005.00561.x
Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M (2006) Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 17(5):205–215. doi:10.1016/j.tem.2006.05.006
Kotani K, Sakane N, Saiga K, Adachi S, Mu H, Kurozawa Y, Kawano M (2006) Serum ghrelin and carotid atherosclerosis in older Japanese people with metabolic syndrome. Arch Med Res 37(7):903–906. doi:10.1016/j.arcmed.2006.03.004
Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, Hosoda H, Kangawa K (2008) Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294(1):H426–H432. doi:10.1152/ajpheart.00643.2007
Xu X, Jhun BS, Ha CH, Jin ZG (2008) Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology 149(8):4183–4192. doi:10.1210/en.2008-0255
Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C, Quon MJ (2007) Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292(3):E756–E764. doi:10.1152/ajpendo.00570.2006
Acknowledgments
The study has been submitted to www.clinicaltrials.gov (ID: NCT00522470). The authors have no duality of interest in regard to this study. The supporting source (Baskent University) had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the report for publication.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berberoglu, Z., Yazici, A.C., Bayraktar, N. et al. Rosiglitazone decreases fasting plasma peptide YY3–36 in type 2 diabetic women: a possible role in weight gain?. Acta Diabetol 49 (Suppl 1), 115–122 (2012). https://doi.org/10.1007/s00592-011-0352-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-011-0352-3